European Journal of Surgical Oncology
Volume 35 , Pages S1-S22 , 2009

Surgical guidelines for the management of breast cancer

References 

  1. Quality assurance guidelines for surgeons in breast cancer screening. NHSBSP Publication No. 20; 1992.
  2. The Breast Surgeons Group of the British Association of Surgical Oncology . Guidelines for surgeons in the management of symptomatic breast disease in the United Kingdom. Eur J Surg Oncol. 1995;21(Suppl. A):1–13
  3. A policy framework for commissioning cancer services: a report by the Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales. London: HMSO; 1995;
  4. The NHS cancer plan – a plan for investment, a plan for reform. London: Department of Health; 2000;
  5. NICE . Improving outcomes in breast cancer – manual update. London: National Institute for Clinical Excellence; 2002;
  6. Cancer Reform Strategy. London: Department of Health; 2007;
  7. Early Breast Cancer Trialists' Collaborative Group . Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview of randomized trials. Lancet. 2005;366:2087–2106
  8. Sainsbury R, Haward B, Rider L, et al. Influence of clinician workload and patterns of treatment on survival from breast cancer. Lancet. 1995;345(8960):1265–1270
  9. Hillner BE, Smith TJ, Desch CE. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol. 2000;18(11):2327–2340
  10. Gillis CR, Hole DJ. Survival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the West of Scotland. BMJ. 1996;312(7024):145–148
  11. Bishop HM, Blamey RW, Morris AH, et al. Bone scanning: its lack of value in the follow up of patients with breast cancer. Br J Surg. 1979;66(10):752–754
  12. The GIVIO Investigators . Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA. 1994;271(20):1587–1592
  13. Khatcheressian JL, Wolff AC, Smith TJ, et al. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guideline in the adjuvant setting. J Clin Oncol. 2006;24(31):5091–5097
  14. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241
  15. Veronesi U, Saccozzi R, Vecchio Del, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;305(1):6–11
  16. Arriagada R, Le MG, Rochard F, et al. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up. J Clin Oncol. 1996;14:1558
  17. Holland R, Veling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–990
  18. van Dongen JA, Bartelink H, Fentiman IS, et al. Factors influencing local relapse and survival and results of salvage treatment after breast-conserving therapy in operable breast cancer: EORTC trial 10801, breast conservation compared with mastectomy in TNM stage I and II breast cancer. Eur J Cancer. 1992;801–805
  19. Dewar JA, Haviland JS, Agrawal RK, et al. Hypofractionation for early breast cancer: first results of the UK standardisation of breast radiotherapy (START) trials. J Clin Oncol. 2007;25(18S):LBA518
  20. Forrest AP, Everington D, McDonald CC, et al. The Edinburgh randomized trial of axillary sampling or clearance after mastectomy. Br J Surg. 1995;82(11):1504–1508
  21. Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys. 1989;17(4):703–710
  22. Siegel BM, Mayzel KA, Love SM. Level I and II axillary dissection in the treatment of early-stage breast cancer. An analysis of 259 consecutive patients. Arch Surg. 1990;125(9):1144–1147
  23. Halverson KJ, Taylor ME, Perez CA, et al. Regional nodal management and patterns of failure following conservative surgery and radiation therapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 1993;26(4):593–599
  24. Chetty U, Jack W, Prescott RJ, et al. Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Edinburgh Breast Unit. Br J Surg. 2000;87(2):163–169
  25. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: The ALMANAC Trial. J Natl Cancer Inst. 2006;98(9):599–609
  26. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996;77(11):2267–2274
  27. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853 – a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381–3387
  28. Holland R, Connolly JL, Gelman R, et al. The presence of an extensive intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol. 1990;8(1):113–118
  29. Salvadori B, Bartoli C, Zurrida S, et al. Risk of invasive cancer in women with lobular carcinoma in situ of the breast. Eur J Cancer. 1991;27(1):35–37
  30. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78(5):1024–1034
  31. Rosen PP, Kosloff C, Lieberman PH, et al. Lobular carcinoma in situ of the breast. Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol. 1978;2(3):225–251
  32. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Cancer. 1996;78(7):1403–1416
  33. Association of Breast Surgery at BASO, the British Association of Plastic, Reconstructive and Aesthetic Surgeons and the Training Interface Group in Breast Surgery . Oncoplastic breast surgery – a guide to good practice. Eur J Surg Oncol. 2007;33:S1–S23
  34. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337(14):949–955
  35. Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999;353(9165):1641–1648
  36. Holmberg L, Garmo H, Granstrand B, et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. J Clin Oncol. 2008;26(8):1247–1252
  37. Houghton J, George WD, Cuzick J, et al. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95–102
  38. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin Oncol. 2001;28(4):400–418
  39. Viani GA, Stefano EJ, Afonso SL, et al. Breast-conserving surgery with or without radiotherapy in women with ductal carcinoma in situ: a meta-analysis of randomized trials. Radiat Oncol. 2007;2:28
  40. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717
  41. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684
  42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–1672
  43. NICE technology appraisal guidance 107. Trastuzumab for the adjuvant treatment of early-stage HER2 positive breast cancer. <www.nice.org.uk/TA107>
  44. Joseph E, Hyacinthe M, Lyman GH, et al. Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer. Ann Surg Oncol. 1998;5(6):522–528
  45. Wheeler T, Stenning S, Negus S, et al. Evidence to support a change in follow-up policy for patients with breast cancer: time to first relapse and hazard rate analysis. Clin Oncol. 1999;11(3):169–173
  46. Ciatto S. Detection of breast cancer local recurrences. Ann Oncol. 1995;6(Suppl. 2):23–26
  47. Gulliford T, Opomu M, Wilson E, et al. Popularity of less frequent follow up for breast cancer in randomised study: initial findings from the hotline study. BMJ. 1997;314(7075):174–177
  48. Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up. JAMA. 1994;271(20):1593–1597
  49. Harries SA, Lawrence RL, Scrivener R, et al. The investigation and treatment of breast cancer in England and Wales. Ann R Coll Surg Engl. 1996;78:197–202
  50. Guidance on screening and symptomatic imaging. 2nd ed.. London: The Royal College of Radiologists; 2003;
  51. The use of imaging in the follow-up of patients with breast cancer. London: The Royal College of Radiologists; 1995;

PII: S0748-7983(09)00027-4

doi: 10.1016/j.ejso.2009.01.008

European Journal of Surgical Oncology
Volume 35 , Pages S1-S22 , 2009

Article Tools